Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Boundless Bio, Inc.BOLD · Entity 7063 | Chief Medical Officer | August 19, 2024 | August 20, 2024 |
| Inhibrx, Inc.INBX · Entity 90351 | Chief Medical Officer | February 16, 2021 | February 18, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Boundless Bio, Inc.
Report date August 19, 2024 · Filed August 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.10 · Expires 2032-02-23 | Direct | 0 |
Reported balance
After 2024-08-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-19 · Disposition to issuer · Disposed 102,564 · Balance 0 F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F1: The stock option vested as to 25% of the underlying shares on February 22, 2023, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.10 · Expires 2032-12-12 | Direct | 0 |
Reported balance
After 2024-08-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-19 · Disposition to issuer · Disposed 9,635 · Balance 0 F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F3: The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.10 · Expires 2033-06-12 | Direct | 0 |
Reported balance
After 2024-08-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-19 · Disposition to issuer · Disposed 94,871 · Balance 0 F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F4: The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.19 · Expires 2034-02-14 | Direct | 0 |
Reported balance
After 2024-08-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-19 · Disposition to issuer · Disposed 68,080 · Balance 0 F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F5: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2034-03-26 | Direct | 0 |
Reported balance
After 2024-08-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-19 · Disposition to issuer · Disposed 41,745 · Balance 0 F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F6: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.56 · Expires 2032-02-23 | Direct | 102,564 |
Reported balance
After 2024-08-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-08-19 · Grant · Acquired 102,564 · Balance 102,564 F7: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F1: The stock option vested as to 25% of the underlying shares on February 22, 2023, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.56 · Expires 2032-12-12 | Direct | 9,635 |
Reported balance
After 2024-08-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-08-19 · Grant · Acquired 9,635 · Balance 9,635 F7: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F3: The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.56 · Expires 2033-06-12 | Direct | 94,871 |
Reported balance
After 2024-08-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-08-19 · Grant · Acquired 94,871 · Balance 94,871 F7: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F4: The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.56 · Expires 2034-02-14 | Direct | 68,080 |
Reported balance
After 2024-08-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-08-19 · Grant · Acquired 68,080 · Balance 68,080 F7: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F5: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.56 · Expires 2034-03-26 | Direct | 41,745 |
Reported balance
After 2024-08-19 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-08-19 · Grant · Acquired 41,745 · Balance 41,745 F7: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F6: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vested as to 25% of the underlying shares on February 22, 2023, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter.
F2: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged.
F3: The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023.
F4: The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023.
F5: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024.
F6: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024.
F7: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability.
Inhibrx, Inc.
Report date February 16, 2021 · Filed February 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 215,150 |
Ending reported balance
After 2021-02-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-16 · Sale · Disposed 156,474 · Balance 234,709 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan on September 14, 2020. F2: The shares were sold in multiple transactions at prices ranging from $22.14 to $32.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Row 2 · 2021-02-17 · Sale · Disposed 19,559 · Balance 215,150 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan on September 14, 2020. F3: The shares were sold in multiple transactions at prices ranging from $25.00 to $25.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan on September 14, 2020.
F2: The shares were sold in multiple transactions at prices ranging from $22.14 to $32.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: The shares were sold in multiple transactions at prices ranging from $25.00 to $25.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2024 Filed Aug 20, 2024 19:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 41,745 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099299 · ownership.xml · derivative · entry 10 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,745 Underlying: Common Stock · 41,745 shares Expires 2034-03-26 F7 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F6 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 68,080 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099299 · ownership.xml · derivative · entry 9 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,080 Underlying: Common Stock · 68,080 shares Expires 2034-02-14 F7 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 94,871 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099299 · ownership.xml · derivative · entry 8 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,871 Underlying: Common Stock · 94,871 shares Expires 2033-06-12 F7 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 9,635 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099299 · ownership.xml · derivative · entry 7 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,635 Underlying: Common Stock · 9,635 shares Expires 2032-12-12 F7 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 102,564 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099299 · ownership.xml · derivative · entry 6 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,564 Underlying: Common Stock · 102,564 shares Expires 2032-02-23 F7 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on February 22, 2023, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 41,745 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-099299 · ownership.xml · derivative · entry 5 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,745 shares Expires 2034-03-26 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F6 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 68,080 | Not disclosed Strike: $8.19 | Not disclosed |
DisclosureSEC source: 0000950170-24-099299 · ownership.xml · derivative · entry 4 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68,080 shares Expires 2034-02-14 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 94,871 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0000950170-24-099299 · ownership.xml · derivative · entry 3 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 94,871 shares Expires 2033-06-12 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 9,635 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0000950170-24-099299 · ownership.xml · derivative · entry 2 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,635 shares Expires 2032-12-12 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 102,564 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0000950170-24-099299 · ownership.xml · derivative · entry 1 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 102,564 shares Expires 2032-02-23 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 7, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on February 22, 2023, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 16:30 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 41,745 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-038700 · ownership.xml · derivative · entry 1 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,745 Underlying: Common Stock · 41,745 shares Expires 2034-03-26 F1 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 17:06 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 19,559 | $25.29 | $494,647.11 |
DisclosureSEC source: 0001739614-21-000039 · wf-form4_161368598906751.xml · nonDerivative · entry 2 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,150 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan on September 14, 2020. F3 · price: The shares were sold in multiple transactions at prices ranging from $25.00 to $25.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 17:06 UTC | Inhibrx, Inc. INBX · Entity 90351 | SaleCommon Stock | 156,474 | $24.32 | $3,805,447.68 |
DisclosureSEC source: 0001739614-21-000039 · wf-form4_161368598906751.xml · nonDerivative · entry 1 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,709 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan on September 14, 2020. F2 · price: The shares were sold in multiple transactions at prices ranging from $22.14 to $32.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 16:14 UTC | Inhibrx, Inc. INBX · Entity 90351 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $33.63 | $0.00 |
DisclosureSEC source: 0001739614-21-000020 · wf-form4_161109088199604.xml · derivative · entry 1 Wagner Klaus W. · CIK 0001766477 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-01-15 F1 · derivative.exercise_date: (1) Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.